Occupational and environmental hepatotoxicity

WikiDoc Resources for Occupational and environmental hepatotoxicity

Articles

Most recent articles on Occupational and environmental hepatotoxicity

Most cited articles on Occupational and environmental hepatotoxicity

Review articles on Occupational and environmental hepatotoxicity

Articles on Occupational and environmental hepatotoxicity in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Occupational and environmental hepatotoxicity

Images of Occupational and environmental hepatotoxicity

Photos of Occupational and environmental hepatotoxicity

Podcasts & MP3s on Occupational and environmental hepatotoxicity

Videos on Occupational and environmental hepatotoxicity

Evidence Based Medicine

Cochrane Collaboration on Occupational and environmental hepatotoxicity

Bandolier on Occupational and environmental hepatotoxicity

TRIP on Occupational and environmental hepatotoxicity

Clinical Trials

Ongoing Trials on Occupational and environmental hepatotoxicity at Clinical Trials.gov

Trial results on Occupational and environmental hepatotoxicity

Clinical Trials on Occupational and environmental hepatotoxicity at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Occupational and environmental hepatotoxicity

NICE Guidance on Occupational and environmental hepatotoxicity

NHS PRODIGY Guidance

FDA on Occupational and environmental hepatotoxicity

CDC on Occupational and environmental hepatotoxicity

Books

Books on Occupational and environmental hepatotoxicity

News

Occupational and environmental hepatotoxicity in the news

Be alerted to news on Occupational and environmental hepatotoxicity

News trends on Occupational and environmental hepatotoxicity

Commentary

Blogs on Occupational and environmental hepatotoxicity

Definitions

Definitions of Occupational and environmental hepatotoxicity

Patient Resources / Community

Patient resources on Occupational and environmental hepatotoxicity

Discussion groups on Occupational and environmental hepatotoxicity

Patient Handouts on Occupational and environmental hepatotoxicity

Directions to Hospitals Treating Occupational and environmental hepatotoxicity

Risk calculators and risk factors for Occupational and environmental hepatotoxicity

Healthcare Provider Resources

Symptoms of Occupational and environmental hepatotoxicity

Causes & Risk Factors for Occupational and environmental hepatotoxicity

Diagnostic studies for Occupational and environmental hepatotoxicity

Treatment of Occupational and environmental hepatotoxicity

Continuing Medical Education (CME)

CME Programs on Occupational and environmental hepatotoxicity

International

Occupational and environmental hepatotoxicity en Espanol

Occupational and environmental hepatotoxicity en Francais

Business

Occupational and environmental hepatotoxicity in the Marketplace

Patents on Occupational and environmental hepatotoxicity

Experimental / Informatics

List of terms related to Occupational and environmental hepatotoxicity

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Synonyms and keywords: Synonym 1; Synonym 2; Synonym 3

## Overview[edit | edit source]

## Historical Perspective[edit | edit source]

* [Disease name] was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event].
* In [year], [gene] mutations were first identified in the pathogenesis of [disease name].
* In [year], the first [discovery] was developed by [scientist] to treat/diagnose [disease name].

## Classification[edit | edit source]

* [Disease name] may be classified according to [classification method] into [number] subtypes/groups:

* [group1]
* [group2]
* [group3]

* Other variants of [disease name] include [disease subtype 1], [disease subtype 2], and [disease subtype 3].

## Pathophysiology[edit | edit source]

* The pathogenesis of [disease name] is characterized by [feature1], [feature2], and [feature3].
* The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway.
* On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
* On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].

## Causes[edit | edit source]

* [Disease name] may be caused by either [cause1], [cause2], or [cause3].
* [Disease name] is caused by a mutation in the [gene1], [gene2], or [gene3] gene[s].
* There are no established causes for [disease name].

## Differentiating [disease name] from other Diseases[edit | edit source]

* [Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:

* [Differential dx1]
* [Differential dx2]
* [Differential dx3]

## Epidemiology and Demographics[edit | edit source]

* The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide.
* In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location].

### Age[edit | edit source]

* Patients of all age groups may develop [disease name].

* [Disease name] is more commonly observed among patients aged [age range] years old.
* [Disease name] is more commonly observed among [elderly patients/young patients/children].

### Gender[edit | edit source]

* [Disease name] affects men and women equally.

* [Gender 1] are more commonly affected with [disease name] than [gender 2].
* The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.

### Race[edit | edit source]

* There is no racial predilection for [disease name].

* [Disease name] usually affects individuals of the [race 1] race.
* [Race 2] individuals are less likely to develop [disease name].

## Risk Factors[edit | edit source]

* Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].

## Screening[edit | edit source]

## Natural History, Complications and Prognosis[edit | edit source]

* The majority of patients with [disease name] remain asymptomatic for [duration/years].
* Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
* If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
* Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
* Prognosis is generally [excellent/good/poor], and the [1/5/10­year mortality/survival rate] of patients with [disease name] is approximately [#%].

## Diagnosis[edit | edit source]

### Diagnostic Criteria[edit | edit source]

* The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met:

* [criterion 1]
* [criterion 2]
* [criterion 3]
* [criterion 4]

### Symptoms[edit | edit source]

* [Disease name] is usually asymptomatic.
* Symptoms of [disease name] may include the following:

* [symptom 1]
* [symptom 2]
* [symptom 3]
* [symptom 4]
* [symptom 5]
* [symptom 6]

### Physical Examination[edit | edit source]

* Patients with [disease name] usually appear [general appearance].
* Physical examination may be remarkable for:

* [finding 1]
* [finding 2]
* [finding 3]
* [finding 4]
* [finding 5]
* [finding 6]

### Laboratory Findings[edit | edit source]

* There are no specific laboratory findings associated with [disease name].

* A [positive/negative] [test name] is diagnostic of [disease name].
* An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name].
* Other laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].

### Imaging Findings[edit | edit source]

* There are no [imaging study] findings associated with [disease name].

* [Imaging study 1] is the imaging modality of choice for [disease name].
* On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3].
* [Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].

### Other Diagnostic Studies[edit | edit source]

* [Disease name] may also be diagnosed using [diagnostic study name].
* Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].

## Treatment[edit | edit source]

### Medical Therapy[edit | edit source]

* There is no treatment for [disease name]; the mainstay of therapy is supportive care.

* The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2].
* [Medical therapy 1] acts by [mechanism of action 1].
* Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].

### Surgery[edit | edit source]

* Surgery is the mainstay of therapy for [disease name].
* [Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name].
* [Surgical procedure] can only be performed for patients with [disease stage] [disease name].

### Prevention[edit | edit source]

* There are no primary preventive measures available for [disease name].

* Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].

* Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].

## References[edit | edit source]